Lee, Eunhyeong
Lee, Eun-Ah
Kong, Eunji
Chon, Haemin
Llaiqui-Condori, Melissa
Park, Cheon Ho
Park, Beom Yong
Kang, Nu Ri
Yoo, Jin-San
Lee, Hyun-Soo
Kim, Hyung-Seok
Park, Sung-Hong http://orcid.org/0000-0002-1731-0668
Choi, Seung-Won http://orcid.org/0000-0003-1203-6126
Vestweber, Dietmar
Lee, Jeong Ho http://orcid.org/0000-0002-2299-630X
Kim, Pilhan http://orcid.org/0000-0001-8388-1840
Lee, Weon Sup
Kim, Injune http://orcid.org/0000-0001-9244-815X
Funding for this research was provided by:
National Research Foundation of Korea (2018R1A2A1A05022672, 2021R1A4A1031198, 2021R1A2C3006538, 2019R1A2C1089108, 2020R1A4A1018714)
KAIST (N11180156, N11180156, N11220110)
Article History
Received: 28 July 2022
Revised: 5 December 2022
Accepted: 8 December 2022
First Online: 24 February 2023
Competing interests
: E.-A.L., C.H.P., B.Y.P., N.K., J.-S.Y. and W.S.L. are coinventors of the 4E2 antibody and stockholders of PharmAbcine Inc., which has the right to use the 4E2 antibody. P.K. is a founder, stockholder, and chief executive officer of IVIM Technology, Inc., which provides intravital confocal and two-photon microscopes. J.H.L. is a co-founder and the chief technology officer of SoVarGen, Inc., which has the right to use the hybrid plasmid for GBM induction. The remaining authors declare no potential conflicts of interest.